Fertility and Sterility
Volume 94, Issue 5 , Pages 1793-1798 , October 2010

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome

Received 10 August 2009 ,Revised 6 October 2009 ,Accepted 8 October 2009.

References 

  1. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod. 2000;15:785–789
  2. Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:186–189
  3. Yildiz BO. Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002;87:3871–3875
  4. Carmassi F, De Negri F, Fioriti R, De Giorgi A, Giannarelli C, Fruzzetti F, et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res. 2005;116:207–214
  5. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:5088–5095
  6. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30:1–50
  7. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951–953
  8. Cheang KI, Nestler JE. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?. Reprod Biomed Online. 2004;8:440–447
  9. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of longterm treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000;85:2767–2774
  10. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol. 2007;157:669–676
  11. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002;17:1729–1737
  12. Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 1999;42:611–619
  13. Hillard PJ. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am. 2005;34:707–723
  14. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003;88:148–156
  15. Calaf J, López E, Millet A, Alcañiz J, Fortuny A, Vidal O, et al. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab. 2007;92:3446–3452
  16. Barth JH, Cherry CA, Wojnarowska F, Dawber RPR. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clin Endocrinol. 1991;35:5–10
  17. Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L, Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem. 1975;6:827–836
  18. Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride and spironolactone to treat idiopathic hirsutism. Fertil Steril. 2003;79:942–946
  19. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod. 2007;22:317–322
  20. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47:277–283
  21. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2007;12:30–35
  22. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004;89:2817–2823
  23. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25
  24. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In:  Dunaif A,  Givens JR,  Haseltine F editor. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992;p. 377–384
  25. De Pirro R, Forte F, Bertoli A, Greco AV, Lauro R. Changes in insulin receptors during oral contraception. J Clin Endocrinol Metab. 1981;52:29–33
  26. Endrikat J, Klipping C, Cronin M, Gerlinger C, Ruebig A, Schmidt W, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 2002;65:215–221
  27. Skouby SO, Andersen O, Saurberey N. Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes. J Clin Endocrinol Metab. 1987;64:519–523
  28. Fruzzetti F, Ricci C, Nicoletti I, Fioretti P. Clinical and metabolic effects of a triphasic pill containing gestodene. Contraception. 1992;46:335–347
  29. Cibula D, Sindelka G, Hill M, Fanta M, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod. 2002;17:76–82
  30. Gaspard UJ, Demeyer F, Jaminet CB, Scheen AJ, Lefebvre PJ. Influence of two low dose oral contraceptives containing ethinylestradiol (20 μg) and desogestrel or gestodene on carbohydrate metabolism during 1 year of use. Gynecol Endocrinol. 1996;10(Suppl 1):179–188
  31. Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception. 2009;79:111–116
  32. Petersen KR, Christiansen E, Madsbad S, Skouby SO, Andersen LF, Jespersen J. Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. Contraception. 1999;60:337–344
  33. Cagnacci A, Paoletti AM, Renzi A, Orrù M, Pilloni M, Melis GB, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptive containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab. 2003;88:3621–3625
  34. Cohen JC, Hickman R. Insulin resistance and decreased tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab. 1987;64:960–963
  35. Corry DB, Tuck M. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep. 2003;5:106–109
  36. Kraus D, Jager J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005;37:455–459
  37. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod. 1998;13:2706–2711
  38. Morin-Papunen L, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2000;85:3161–3168

 F.F. has nothing to disclose. D.P. has nothing to disclose. V.L. has nothing to disclose. D.P. has nothing to disclose. M.G. has nothing to disclose. A.R.G. has nothing to disclose.

PII: S0015-0282(09)03876-X

doi: 10.1016/j.fertnstert.2009.10.016

Fertility and Sterility
Volume 94, Issue 5 , Pages 1793-1798 , October 2010

Article Tools

* Image Usage & Resolution